NCT03070392 · OUTCOME

Efficacy: Duration of Response (DOR)

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma · Source last updated 2026-03-17

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: DOR will be assessed every 3 months from randomization until disease progression, assessed up to 5.5 years.

What was measured

Duration of response (DOR) is defined as the time from first documented objective response (RECIST v1.1) until the date of documented disease progression.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Duration of response (DOR) is defined as the time from first documented objective response (RECIST v1.1) until the date of documented disease progression.
reporting Status: NOT_POSTED
time Frame: DOR will be assessed every 3 months from randomization until disease progression, assessed up to 5.5 years.
title: Efficacy: Duration of Response (DOR)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice